|
1) Bashir R, Britton S, Strachan T, et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet. 1998; 20: 37-42
|
|
|
|
2) Weiler T, Bashir R, Anderson LV, et al. Identical mutation in patients with limb girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s). Hum Mol Genet. 1999; 8: 871-7
|
|
|
|
|
|
3) Washington NL, Ward S. FER-1 regulates Ca2＋-mediated membrane fusion during C. elegans spermatogenesis. J Cell Sci. 2006; 119: 2552-62
|
|
|
|
|
|
4) Bansal D, Miyake K, Vogel SS, et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature. 2003; 423: 168-72
|
|
|
|
|
|
5) Lennon NJ, Kho A, Bacskai BJ, et al. Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Biol Chem. 2003; 278: 50466-73
|
|
|
|
|
|
6) Ward S, Argon Y, Nelson GA. Sperm morphogenesis in wild-type and fertilization-defective mutants of Caenorhabditis elegans. J Cell Biol. 1981; 91: 26-44
|
|
|
|
|
|
7) Achanzar WE, Ward S. A nematode gene required for sperm vesicle fusion. J Cell Sci. 1997; 110: 1073-81
|
|
|
|
|
|
8) Steinhardt RA, Bi G, Alderton JM. Cell membrane resealing by a vesicular mechanism similar to neurotransmitter release. Science. 1994; 263: 390-3
|
|
|
|
|
|
9) Bi GQ, Morris RL, Liao G, et al. Kinesin- and myosin-driven steps of vesicle recruitment for Ca2＋-regulated exocytosis. J Cell Biol. 1997; 138: 999-1008
|
|
|
|
|
|
10) Miyake K, McNeil PL. Vesicle accumulation and exocytosis at sites of plasma membrane disruption. J Cell Biol. 1995; 131: 1737-45
|
|
|
|
|
|
11) Reddy A, Caler EV, Andrews NW. Plasma membrane repair is mediated by Ca2＋-regulated exocytosis of lysosomes. Cell. 2001; 106: 157-69
|
|
|
|
|
|
12) Anderson LV, Davison K, Moss JA, et al. Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet. 1999; 8: 855-61
|
|
|
|
|
|
13) Glover L, Brown RH Jr. Dysferlin in membrane trafficking and patch repair. Traffic. 2007; 8: 785-94
|
|
|
|
|
|
14) Nalefski EA, Falke JJ. The C2 domain calcium-binding motif: structural and functional diversity. Protein Sci. 1996; 5: 2375-90
|
|
|
|
|
|
15) Yasunaga S, Grati M, Cohen-Salmon M, et al. A mutation in OTOF, encoding otoferlin, a FER-1-like protein, causes DFNB9, a nonsyndromic form of deafness. Nat Genet. 1999; 21: 363-9
|
|
|
|
|
|
16) Doherty KR, Cave A, Davis DB, et al. Normal myoblast fusion requires myoferlin. Development. 2005; 132: 5565-75
|
|
|
|
|
|
17) Doherty KR, McNally EM. Repairing the tears: dysferlin in muscle membrane repair. Trends Mol Med. 2003; 9: 327-30
|
|
|
|
|
|
18) Davis DB, Doherty KR, Delmonte AJ, et al. Calcium-sensitive phospholipid binding properties of normal and mutant ferlin C2 domains. J Biol Chem. 2002; 277: 22883-8
|
|
|
|
|
|
19) Chapman ER. Synaptotagmin: a Ca2＋ sensor that triggers exocytosis？ Nat Rev Mol Cell Biol. 2002; 3: 498-508
|
|
|
|
|
|
20) Augustine GJ. How does calcium trigger neurotransmitter release？ Curr Opin Neurobiol. 2001; 11: 320-6
|
|
|
|
|
|
21) Piccolo F, Moore SA, Ford GC, et al. Intracellular accumulation and reduced sarcolemmal expression of dysferlin in limb-girdle muscular dystrophies. Ann Neurol. 2000; 48: 902-12
|
|
|
|
|
|
22) Selcen D, Stilling G, Engel AG. The earliest pathologic alterations in dysferlinopathy. Neurology. 2001; 56: 1472-81
|
|
|
|
|
|
23) Dalkilic I, Kunkel LM. Muscular dystrophies: genes to pathogenesis. Curr Opin Genet Dev. 2003; 13: 231-8
|
|
|
|
|
|
24) Durbeej M, Campbell KP. Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. Curr Opin Genet Dev. 2002; 12: 349-61
|
|
|
|
|
|
25) Ho M, Post CM, Donahue LR, et al. Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Hum Mol Genet. 2004; 13: 1999-2010
|
|
|
|
|
|
26) McNeil PL, Terasaki M. Coping with the inevitable: how cells repair a torn surface membrane. Nat Cell Biol. 2001; 3: E124-9
|
|
|
|
|
|
27) Raynal P, Pollard HB. Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim Biophys Acta. 1994; 1197: 63-93
|
|
|
|
|
|
28) Huang Y, Laval SH, van Remoortere A, et al. AHNAK, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration. FASEB J. 2007; 21: 732-42
|
|
|
|
|
|
29) Benaud C, Gentil BJ, Assard N, et al. AHNAK interaction with the annexin 2/S100A10 complex regulates cell membrane cytoarchitecture. J Cell Biol. 2004; 164: 133-44
|
|
|
|
|
|
30) Matsuda C, Kameyama K, Tagawa K, et al. Dysferlin interacts with affixin (beta-parvin) at the sarcolemma. J Neuropathol Exp Neurol. 2005; 64: 334-40
|
|
|
|
|
|
31) Yamaji S, Suzuki A, Sugiyama Y, et al. A novel integrin-linked kinase-binding protein, affixin, is involved in the early stage of cell-substrate interaction. J Cell Biol. 2001; 153: 1251-64
|
|
|
|
|
|
32) Minetti C, Sotgia F, Bruno C, et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet. 1998; 18: 365-8
|
|
|
|
|
|
33) Betz RC, Schoser BG, Kasper D, et al. Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease. Nat Genet. 2001; 28: 218-9
|
|
|
|
|
|
34) Shaul PW, Anderson RG. Role of plasmalemmal caveolae in signal transduction. Am J Physiol. 1998; 275: L843-51
|
|
|
|
|
|
35) Parton RG, Way M, Zorzi N, et al. Caveolin-3 associates with developing T-tubules during muscle differentiation. J Cell Biol. 1997; 136: 137-54
|
|
|
|
|
|
36) Crosbie RH, Yamada H, Venzke DP, et al. Caveolin-3 is not an integral component of the dystrophin glycoprotein complex. FEBS Lett. 1998; 427: 279-82
|
|
|
|
|
|
37) Matsuda C, Hayashi YK, Ogawa M, et al. The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle. Hum Mol Genet. 2001; 10: 1761-6
|
|
|
|
|
|
38) Hernandez-Deviez DJ, Martin S, Laval SH, et al. Aberrant dysferlin trafficking in cells lacking caveolin or expressing dystrophy mutants of caveolin-3. Hum Mol Genet. 2006; 15: 129-42
|
|
|
|
|
|
39) Ampong BN, Imamura M, Matsumiya T, et al. Intracellular localization of dysferlin and its association with the dihydropyridine receptor. Acta Myol. 2005; 24: 134-44
|
|
|
|
|
|
40) Anderson LV, Harrison RM, Pogue R, et al. Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies). Neuromuscul Disord. 2000; 10: 553-9
|
|
|
|
|
|
41) Chrobakova T, Hermanova M, Kroupova I, et al. Mutations in Czech LGMD2A patients revealed by analysis of calpain3 mRNA and their phenotypic outcome. Neuromuscul Disord. 2004; 14: 659-65
|
|
|
|
|
|
42) Goll DE, Thompson VF, Li H, et al. The calpain system. Physiol Rev. 2003; 83: 731-801
|
|
|
|
|
|
43) Huang Y, Verheesen P, Roussis A, et al. Protein studies in dysferlinopathy patients using llama-derived antibody fragments selected by phage display. Eur J Hum Genet. 2005; 13: 721-30
|
|
|
|
|
|
44) Wenzel K, Carl M, Perrot A, et al. Novel sequence variants in dysferlin-deficient muscular dystrophy leading to mRNA decay and possible C2-domain misfolding. Hum Mutat. 2006; 27: 599-600
|
|
|
|
|
|
45) Fujita E, Kouroku Y, Isoai A, et al. Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/proteasome ERAD(I) and autophagy/lysosome ERAD(II). Hum Mol Genet. 2007; 16: 618-29
|
|
|
|
|